Dermot Kenny

Dermot Kenny

Auto-generated profile, based on publicly available information

Dermot Kenny

Royal College of Surgeons in Ireland

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarco Cattaneo
Marco Cattaneo
CCChiara Cerletti
Chiara Cerletti
PHPaul Harrison
Paul Harrison
CHC. P. M. Hayward
C. P. M. Hayward
DKD. Kenny
D. Kenny
AMA. D. Michelson
A. D. Michelson
Click on the article title to read more.

18 November 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PGPaolo Gresele
Paolo Gresele
PHPaul Harrison
Paul Harrison
CGC. Gachet
C. Gachet
CHC. Hayward
C. Hayward
DKD. Kenny
D. Kenny
TPThe Subcommittee On Platelet Physiology
The Subcommittee On Platelet Physiology

7 July 2006 in Circulation Research
Verified
Journal Article
Closed access
MSMeike Schwarz
Meike Schwarz
GMGerardene Meade
Gerardene Meade
PSPatrick Stoll
Patrick Stoll
JYJari Ylanne
Jari Ylanne
NBNicole Bassler
Nicole Bassler
KPKarlheinz Peter
Karlheinz Peter
Platelet activation causes conformational changes of integrin GPIIb/IIIa (αIIbβ3), resulting in the exposure of its ligand-binding pocket. This provides the unique possibility to design agents that specifically block activated platelets only. We used phage display of single-chain antibody (scFv) libraries in combination with several rounds of depletion/selection to obtain human scFvs that bind specifically to the activated conformation of GPIIb/IIIa. Functional evaluation of these scFv clones revealed that fibrinogen binding to human platelets and platelet aggregation can be effectively inhibited by activation-specific scFvs. In contrast to clinically used GPIIb/IIIa blockers, which are all conformation unspecific, activation-specific GPIIb/IIIa blockers do not induce conformational changes in GPIIb/IIIa or outside-in signaling, as evaluated by ligand-induced binding-site (LIBS) exposure in flow cytometry or P-selectin expression in immunofluorescence microscopy, respectively. In contrast to the conformation-unspecific blocker abciximab, activation-specific scFvs permit cell adhesion and spreading on immobilized fibrinogen, which is mediated by nonactivated GPIIb/IIIa. Mutagenesis studies and computer modeling indicate that exclusive binding of activation-specific scFv is mediated by RXD motifs in the heavy-chain complementary-determining region (CDR) 3 of the antibodies, which in comparison with other antibodies forms an exceptionally extended loop. In vivo experiments in a ferric-chloride thrombosis model of the mouse carotid artery demonstrate similar antithrombotic potency of activation-specific scFv, when compared with the conformation-unspecific blockers tirofiban and eptifibatide. However, in contrast to tirofiban and eptifibatide, bleeding times are not prolonged with the activation-specific scFvs, suggesting lower bleeding risks. In conclusion, activation-specific GPIIb/IIIa blockade via human single-chain antibodies represents a promising novel strategy for antiplatelet therapy.

30 June 2014 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
PGPaolo Gresele
Paolo Gresele
PHPaul Harrison
Paul Harrison
Loredana BuryLoredana Bury
Loredana Bury
EFE. Falcinelli
E. Falcinelli
CGC. Gachet
C. Gachet
MCMarco Cattaneo
Marco Cattaneo
Background Diagnosis of inherited platelet function disorders (IPFDs) is important for appropriate management and to improve epidemiologic and clinical knowledge. However, there remains a lack of consensus on the diagnostic approach. Objectives To gain knowledge on the current practices for the diagnosis of IPFD worldwide. Methods A 67‐item questionnaire was distributed to the ISTH members and to the members of several national hemostasis and thrombosis societies. Results A total of 202 laboratories from 37 countries participated in the survey. The most frequent criterion to define patients with a suspected IPFD was a history of mucocutaneous bleeding and no acquired cause, but heterogeneity on the identification criteria was evident. Only 64.5% of respondents performed a direct clinical interview. On average, each laboratory studied 72 patients per year. The most commonly used laboratory equipment were the light‐transmission aggregometer, the Platelet Function Analyzer‐100, and the flow cytometer. Screening tests were platelet count, peripheral blood smear, light‐transmission aggregometry, and Platelet Function Analyzer‐100. Second‐step tests were flow cytometry, molecular genetic analysis, and electron microscopy. Methodologies varied widely. In total, ~ 14 000 patients were investigated yearly and 60% turned out to not have a defect. Of the remaining 40%, only 8.7% received a diagnosis at a molecular level. Conclusions Many laboratories worldwide are involved in the diagnosis of IPFD. A large fraction of the patients studied remain without a diagnosis. A high variability in the diagnostic approaches is evident.

12 October 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KEKarl Egan
Karl Egan
DCDarragh Crowley
Darragh Crowley
PSPaul Smyth
Paul Smyth
SOSharon O'toole
Sharon O'toole
CSCathy Spillane
Cathy Spillane
JOJohn O'leary
John O'leary
Thrombosis is common in ovarian cancer. However, the interaction of platelets with ovarian cancer cells has not been critically examined. To address this, we investigated platelet interactions in a range of ovarian cancer cell lines with different metastatic potentials [HIO-80, 59M, SK-OV-3, A2780, A2780cis]. Platelets adhered to ovarian cancer cells with the most significant adhesion to the 59M cell line. Ovarian cancer cells induced platelet activation [P-selectin expression] in a dose dependent manner, with the most significant activation seen in response to the 59M cell line. The platelet antagonists [cangrelor, MRS2179, and apyrase] inhibited 59M cell induced activation suggesting a P2Y12 and P2Y1 receptor mediated mechanism of platelet activation dependent on the release of ADP by 59M cells. A2780 and 59M cells potentiated PAR-1, PAR-4, and TxA2 receptor mediated platelet activation, but had no effect on ADP, epinephrine, or collagen induced activation. Analysis of gene expression changes in ovarian cancer cells following treatment with washed platelets or platelet releasate showed a subtle but valid upregulation of anti-apoptotic, anti-autophagy pro-angiogenic, pro-cell cycle and metabolic genes. Thus, ovarian cancer cells with different metastatic potential adhere and activate platelets differentially while both platelets and platelet releasate mediate pro-survival and pro-angiogenic signals in ovarian cancer cells.

19 June 2014 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
KEKarl Egan
Karl Egan
NCNiamh Cooke
Niamh Cooke
DKDermot Kenny
Dermot Kenny